H5N1 News and Research

Latest H5N1 News and Research

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

CEL-SCI expands licensing agreement with Teva for Multikine cancer drug

20 Jul 2011
Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

Positive data from Inovio's VGX-3400X Phase I study against H5N1 influenza

14 Jul 2011
Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

Positive final results from Medicago's H5N1 Avian Influenza VLP vaccine Phase II trial

30 Jun 2011
Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

Teva concludes Site Initiation Visit for Israeli clinical center in CEL-SCI's Multikine Phase III clinical trial

27 Jun 2011
Biota reports preliminary data from CS-8958 Phase III trial against influenza

Biota reports preliminary data from CS-8958 Phase III trial against influenza

27 Jun 2011
Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer

24 Jun 2011
CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

CEL-SCI announces results from Multikine Phase II trial on head and neck cancer

22 Jun 2011
NanoViricides plans to lease new cGMP manufacturing and lab space

NanoViricides plans to lease new cGMP manufacturing and lab space

20 Jun 2011
CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

13 Jun 2011
NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

7 Jun 2011
Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

Positive results from CEL-SCI's LEAPS H1N1-activated dendritic cells trial in mice

27 May 2011
Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

26 May 2011
Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

23 May 2011
CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

CEL-SCI initiates global Multikine Phase III trial for head and neck cancer in Russia

20 May 2011
CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

18 May 2011
CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

13 May 2011
Sinovac first quarter sales increase 5.3% to $4.7 million

Sinovac first quarter sales increase 5.3% to $4.7 million

13 May 2011
Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

Aethlon seeks FDA meeting for re-initiation of Hemopurifier IDE study

10 May 2011
CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

CEL-SCI receives Polish government approval to commence Multikine Phase III clinical trial in head, neck cancer

5 May 2011
NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

NanoViricides' FluCide drug candidate greatly reduces lung viral load in animals

3 May 2011

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback